Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Data from regulatory stud… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Data from regulatory studies: What do they tell? What don't they tell?

Artikel i vetenskaplig tidskrift
Författare Elinor Ben-Menachem
Publicerad i Acta neurologica Scandinavica. Supplementum
Volym 181
Sidor 21-5
ISSN 0065-1427
Publiceringsår 2005
Publicerad vid Institutionen för klinisk neurovetenskap, Sektionen för kliniska nervsjukdomar
Sidor 21-5
Språk en
Länkar dx.doi.org/10.1111/j.1600-0404.2005...
Ämnesord Adverse Drug Reaction Reporting Systems, Anticonvulsants, adverse effects, therapeutic use, Clinical Trials, Phase III as Topic, legislation & jurisprudence, Clinical Trials, Phase IV as Topic, legislation & jurisprudence, Drug Approval, legislation & jurisprudence, Drug Interactions, Epilepsy, drug therapy, Follow-Up Studies, Humans, Product Surveillance, Postmarketing, Prospective Studies, Risk Assessment, Treatment Outcome, United States
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

Phase III studies of antiepileptic drugs (AEDs) are specifically designed to satisfy strict regulatory criteria. As they are conducted in protocol-restricted patient populations over short treatment periods and employ fixed study designs and dosing schedules, they are not fully representative of 'real-life' clinical practice. Therefore, in order to provide an overall assessment of clinical performance, regulatory studies must be backed up by post-marketing clinical experience. Phase IV studies provide information on a drug's performance in a setting more closely representing real clinical practice, with broader patient populations and a more flexible approach to individual treatment. Prospective long-term studies allow the determination of efficacy and safety (and cost-effectiveness) over extended treatment periods; these studies and audit data provide a means of assessing idiosyncratic side effects, unusual interactions and the effects of an AED in rare patient groups. By complementing regulatory evidence with real-life clinical experience, a comprehensive assessment of the risks and benefits of an AED can be made.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?publicationId=98699
Utskriftsdatum: 2019-11-17